Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics
The options for male contraceptives are limited. Research is ongoing to develop a male contraceptive based on hormonal activity. Testosterone is one of the hormones necessary in producing sperm. Testosterone is absolutely required as a hormone for male fertility. Derivatives of testosterone for male contraceptives currently in clinical trials are associated with estrogenic deficiency. This deficiency can cause several issues including, but not limited to, bone density loss, risk of obesity, cardiovascular disease, and/or ineffective carbohydrate or lipid metabolism.
Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.
PET Imaging Agents for Fungal Infections
Available for licensing and commercial development are patent rights covering PET imaging agents, methods of their synthesis, and their uses in imaging specific fungal infections.
Humanized 40H3 Antibody
Summary:
The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.
Novel Antigen for Use as Vaccine Against Nematode Infection
Compositions and Methods for Detecting Loa loa
Humanized Monoclonal Antibodies Specific Against Human Soluble Tissue Factor (hsTF) as Diagnosis, Prevention and Therapeutic Agents for Thrombosis
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel humanized monoclonal antibody (58B3) that selectively targets a newly identified soluble Tissue Factor (sTF) to diagnose, prevent and treat pathological thrombosis associated with inflammation, viral/bacterial infection, sepsis and cancer – without affecting normal hemostasis.
Real-time AI System for Echocardiography Analysis and Quantification
Summary:
We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology.
ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage
Summary:
The National Cancer Institute (NCI) seeks co-development partners and/or licensees to further develop a novel ELISA-based biodosimeter.